Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87.

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

Boston Scientific (NYSE:BSX) reported fiscal Q4 2024 results that surpassed analyst expectations. The company's shares swung between gains and losses in premarket trading Wednesday. The company ...

Boston Common Asset Management LLC boosted its holdings in shares of NVIDIA Co. (NASDAQ:NVDA – Free Report) by 50.4% during the fourth quarter, according to its most recent Form 13F filing with the ...

Trump's pick to run the Department of Health and Human Services gave away the agenda -- and may have invited a strong legal ...

Explore the debate on climate change causes: human activities vs. natural variability. Discover the latest data, scientific ...

The following first ran on CounterPunch at the height of the COVID pandemic in January of 2022. Are anti-vaccine ...

The man who hopes to be President Donald Trump’s health secretary said he needed to see data showing vaccines are safe, but ...

Report’s recommendations included that the use of COVID-19 vaccines be halted unless more information is provided about risk ...

The S&P 500 Index ( $SPX) ( SPY) today is up +0.24%, the Dow Jones Industrials Index ( $DOWI ) ( DIA) is up +0.33%, and the Nasdaq 100 Index ( $IUXX) ( QQQ) is up +0.17%. March E-mini S&P futures ( ...

For fiscal year 2027, Eurofins reiterated an average of 6.5% organic growth and confirmed a 24% EBITDA margin target, although it has abandoned its €10 billion revenue goal and now expects further ...

Trump seems intent on freezing out professional scientists, especially those with strong academic research backgrounds.